PDA 002

Drug Profile

PDA 002

Alternative Names: PDA-002; PDAC cells; Placental-derived adherent cells intramuscular

Latest Information Update: 09 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Celgene Corporation
  • Class Antiulcers; Skin disorder therapies; Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diabetic foot ulcer; Diabetic neuropathies; Peripheral arterial disorders

Most Recent Events

  • 01 Oct 2016 Celgene completes a phase I trial in Peripheral arterial disorders and Diabetic foot ulcer in USA (IM) (NCT01859117)
  • 20 Apr 2016 Celgene Corporation withdraws a phase II trial in Peripheral arterial disorders and Diabetic foot ulcers prior to enrolment in USA (IM) (NCT02460081)
  • 01 Sep 2015 Phase-II clinical trials in Diabetic neuropathies in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top